Ambu A/S (AMBU-B.CO)
DKK 107.2
(3.08%)
DKK 107.2
(3.08%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 691 Million DKK | 14.98% |
| 2023 | 601 Million DKK | 26.87% |
| 2022 | 442 Million DKK | -12.08% |
| 2021 | 494 Million DKK | -2.76% |
| 2020 | 521 Million DKK | -4.77% |
| 2019 | 608 Million DKK | -10.98% |
| 2018 | 616 Million DKK | 30.84% |
| 2017 | 531 Million DKK | 12.5% |
| 2016 | 456 Million DKK | 28.53% |
| 2015 | 340 Million DKK | 14.97% |
| 2014 | 314 Million DKK | 41.44% |
| 2013 | 164 Million DKK | 2.57% |
| 2012 | 202 Million DKK | 7.66% |
| 2011 | 201.02 Million DKK | 8.19% |
| 2010 | 182.36 Million DKK | 35.03% |
| 2009 | 137.6 Million DKK | 153.18% |
| 2008 | 121.73 Million DKK | -342.41% |
| 2007 | 106.73 Million DKK | -12.32% |
| 2006 | 120.63 Million DKK | 76.34% |
| 2005 | 69.03 Million DKK | 21.82% |
| 2004 | 98.87 Million DKK | -6.62% |
| 2003 | 60.68 Million DKK | 40.89% |
| 2002 | 43.07 Million DKK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 216 Million DKK | 68.75% |
| 2024 Q3 | 270 Million DKK | -5.26% |
| 2024 Q2 | 285 Million DKK | 31.94% |
| 2023 Q3 | 177 Million DKK | 43.9% |
| 2023 Q1 | 146 Million DKK | 4.29% |
| 2023 FY | - DKK | 26.87% |
| 2023 Q4 | 183 Million DKK | 3.39% |
| 2023 Q2 | 123 Million DKK | -15.75% |
| 2022 Q2 | 267 Million DKK | 169.7% |
| 2022 FY | - DKK | -12.08% |
| 2022 Q3 | 130 Million DKK | -51.31% |
| 2022 Q4 | 140 Million DKK | 7.69% |
| 2022 Q1 | 99 Million DKK | 47.76% |
| 2021 FY | - DKK | -2.76% |
| 2021 Q1 | 183 Million DKK | 56.41% |
| 2021 Q2 | 169 Million DKK | -7.65% |
| 2021 Q3 | 144 Million DKK | -14.79% |
| 2021 Q4 | 67 Million DKK | -53.47% |
| 2020 Q2 | 210 Million DKK | 92.66% |
| 2020 FY | - DKK | -4.77% |
| 2020 Q4 | 117 Million DKK | -32.37% |
| 2020 Q3 | 173 Million DKK | -17.62% |
| 2020 Q1 | 109 Million DKK | 255.71% |
| 2019 Q2 | 226 Million DKK | 64.96% |
| 2019 Q1 | 137 Million DKK | -29.74% |
| 2019 Q4 | -70 Million DKK | -122.22% |
| 2019 FY | - DKK | -10.98% |
| 2019 Q3 | 315 Million DKK | 39.38% |
| 2018 Q1 | 112 Million DKK | -21.13% |
| 2018 FY | - DKK | 30.84% |
| 2018 Q2 | 172 Million DKK | 53.57% |
| 2018 Q3 | 204 Million DKK | 18.6% |
| 2018 Q4 | 195 Million DKK | -4.41% |
| 2017 Q3 | 127 Million DKK | -10.56% |
| 2017 Q1 | 111 Million DKK | -26.97% |
| 2017 Q4 | 142 Million DKK | 11.81% |
| 2017 FY | - DKK | 12.5% |
| 2017 Q2 | 142 Million DKK | 27.93% |
| 2016 Q4 | 152 Million DKK | 17.83% |
| 2016 Q2 | 100 Million DKK | 20.48% |
| 2016 Q1 | 83 Million DKK | -27.19% |
| 2016 FY | - DKK | 28.53% |
| 2016 Q3 | 129 Million DKK | 29.0% |
| 2015 FY | - DKK | 14.97% |
| 2015 Q4 | 114 Million DKK | 128.0% |
| 2015 Q3 | 50 Million DKK | -67.11% |
| 2015 Q2 | 152 Million DKK | 181.48% |
| 2015 Q1 | 54 Million DKK | -56.8% |
| 2014 Q3 | 78 Million DKK | 41.82% |
| 2014 Q4 | 125 Million DKK | 60.26% |
| 2014 FY | - DKK | 41.44% |
| 2014 Q1 | 16 Million DKK | -61.72% |
| 2014 Q2 | 55 Million DKK | 243.75% |
| 2013 Q3 | 39.1 Million DKK | -37.34% |
| 2013 Q4 | 41.8 Million DKK | 6.91% |
| 2013 FY | - DKK | 2.57% |
| 2013 Q1 | 34 Million DKK | -44.92% |
| 2013 Q2 | 62.4 Million DKK | 83.53% |
| 2012 Q2 | 57.9 Million DKK | 51.17% |
| 2012 Q1 | 38.3 Million DKK | 77.09% |
| 2012 FY | - DKK | 7.66% |
| 2012 Q4 | 61.72 Million DKK | 1.53% |
| 2012 Q3 | 60.8 Million DKK | 5.01% |
| 2011 Q4 | 21.62 Million DKK | -51.51% |
| 2011 Q2 | 94.6 Million DKK | 135.91% |
| 2011 FY | - DKK | 8.19% |
| 2011 Q1 | 40.1 Million DKK | 7.07% |
| 2011 Q3 | 44.6 Million DKK | -52.85% |
| 2010 Q1 | 37.6 Million DKK | 148.91% |
| 2010 Q2 | 57.4 Million DKK | 52.66% |
| 2010 FY | - DKK | 35.03% |
| 2010 Q4 | 37.45 Million DKK | -34.29% |
| 2010 Q3 | 57 Million DKK | -0.7% |
| 2009 Q4 | 15.1 Million DKK | -68.98% |
| 2009 Q1 | 36 Million DKK | 0.0% |
| 2009 Q2 | 50.9 Million DKK | 41.39% |
| 2009 FY | - DKK | 153.18% |
| 2009 Q3 | 48.7 Million DKK | -4.32% |
| 2008 FY | - DKK | -342.41% |
| 2007 FY | - DKK | -12.32% |
| 2006 FY | - DKK | 76.34% |
| 2005 FY | - DKK | 21.82% |
| 2004 FY | - DKK | -6.62% |
| 2003 FY | - DKK | 40.89% |
| 2002 FY | - DKK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ChemoMetec A/S | 193.97 Million DKK | -256.228% |
| Demant A/S | 5.21 Billion DKK | 86.757% |
| GN Store Nord A/S | 2.31 Billion DKK | 70.125% |
| Scandinavian Medical Solutions A/S | 21.22 Million DKK | -3155.536% |
| ViroGates A/S | -12.48 Million DKK | 5636.415% |